RxDoctor Payments Data

Danielle Bartley, NP

Family · Martins Ferry, OHNPI 1790083251

Payments from drug & device makers

$11,012in general payments, 2019–2025

Across 324 payments — averaging $33.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Alkermes, Inc.$520
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$462
  • Axsome Therapeutics, Inc.$324
  • Vanda Pharmaceuticals Inc.$315
  • Lundbeck LLC$213
  • plus $561 from 6 others

What the payments were for

  • Speaking & faculty fees$6,25057%
  • Food & beverage$4,71543%
  • Education$470%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,012 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$6,797
Medicare patients
38
Services billed
119

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine63$629,145
VraylarCariprazine Hcl179$255,135
IngrezzaValbenazine Tosylate12$96,684
CaplytaLumateperone Tosylate33$57,079
RexultiBrexpiprazole35$50,704
Wellbutrin XlBupropion Hcl14$26,918
AuvelityDextromethorphan Hbr/Bupropion20$23,988
TrintellixVortioxetine Hydrobromide31$14,756
Aripiprazole117$13,286
Lurasidone Hcl38$10,660
Asenapine Maleate15$8,255
Paliperidone ErPaliperidone30$7,320
Buspirone Hcl351$6,531
Oxcarbazepine144$4,431
Trazodone Hcl208$3,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Austedo$20$629,14563 claims
AbbVieVraylar$8,616$255,135179 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$462$57,07933 claims
Otsuka America Pharmaceutical, Inc.Rexulti$190$50,70435 claims
Axsome Therapeutics, Inc.Auvelity$324$23,98820 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$11$14,75631 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Martins Ferry

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →